Thu, Apr 24, 2014, 11:51 AM EDT - U.S. Markets close in 4 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • rareearth42 rareearth42 Mar 28, 2006 5:54 PM Flag

    Any scientists here?

    I've been looking at SNSS and haven't been able to figure out precisely how their '595 drug works to trigger apoptosis. I did see that it induced caspase 3 and p21 activation, but not how that happened.

    Does anyone know?

    Thanks,

    RE42

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From Sunesis press release:

      SNS-595 is a promising first-in-class cancer therapeutic currently in a Phase I acute leukemia clinical trial and Phase II non-small cell and small cell lung cancer clinical studies. SNS-595, a naphthyridine analog, has a novel mechanism of action that selectively targets and kills proliferating cells during the DNA replication phase of the cell cycle. SNS-595 works through the DNA-protein kinase and p73 dependent pathways to induce apoptosis, or programmed cell death. In clinical trials conducted to date, SNS-595 has been well tolerated and has shown promising signs of clinical activity. In earlier preclinical evaluation, SNS-595 demonstrated broad and potent activity across xenograft, syngeneic and drug-resistant models.

 
SNSS
5.39+0.03(+0.53%)11:50 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.